NIKKEI 225
37,999.47 -229.64 (-0.60%) HANG SENG
18,865.94 -97.74 (-0.52%) CRUDE OIL
77.81 -0.45 (-0.58%) GOLD FUTURES
2,362.70 -12.30 (-0.52%) DOW
39,512.84 +837.14 (+2.16%) Bitcoin GBP
48,938.32 +310.74 (+0.64%)
Cytosorbents Corporation (HQE1.F)
| Previous close | 0.7690 |
| Open | 0.7250 |
| Bid | 0.0000 x 160000 |
| Ask | 0.0000 x 150000 |
| Day's range | 0.7250 - 0.7250 |
| 52-week range | 0.7000 - 3.6000 |
| Volume | |
| Avg. volume | 7 |
| Market cap | 23.834M |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6460 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.60 |
Simply Wall St.Cytosorbents First Quarter 2024 Earnings: In Line With Expectations
Cytosorbents ( NASDAQ:CTSO ) First Quarter 2024 Results Key Financial Results Revenue: US$9.79m (up 3.6% from 1Q 2023...
Insider MonkeyCytosorbents Corporation (NASDAQ:CTSO) Q1 2024 Earnings Call Transcript
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2024 Earnings Call Transcript May 9, 2024 Cytosorbents Corporation beats earnings expectations. Reported EPS is $-0.11717, expectations were $-0.12. Cytosorbents Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to CytoSorbents’ First […]
GlobeNewswireCytoSorbents Reports First Quarter 2024 Results
Product Sales up a robust 14% over prior year, and a significant 22% sequentiallyWe believe the STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary artery bypass graft (CABG) patients On track for U.S. Food and Drug Administration (FDA) De Novo and Health Canada submissions for DrugSorb®-ATR in Q3 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood pu
